YAP overexpression was observed in tumors harboring a BRAF mutation from patients with melanoma or NSCLC, and YAP expression levels inversely correlated to the patients’ initial response to RAF and MEK inhibition. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.